Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Oncology biotechnology firm Exelixis (EXEL) is highlighted by Zacks as a top momentum stock, underscored by its 'A' Momentum and VGM Style Scores despite a #3 (Hold) Zacks Rank. The company has experienced a 6.4% share price increase over the past four weeks, fueled by 10 upward analyst revisions for fiscal 2025 earnings estimates, raising the consensus to $2.64 per share, and a robust average earnings surprise of +48.6%. This data suggests strong positive momentum and analyst confidence in EXEL's near-term outlook.

Analysis

Exelixis (EXEL) presents a strong momentum case backed by improving analyst sentiment and a history of operational outperformance. The stock has gained 6.4% over the past four weeks, a move supported by its 'A' grade for Momentum in the Zacks Style Score system. This price action is underpinned by a significant shift in forward-looking expectations, with 10 analysts revising fiscal 2025 earnings estimates upward in the last 60 days. This collective revision has lifted the Zacks Consensus Estimate for that period by $0.33 to $2.64 per share. Further bolstering confidence is the company's track record of delivering an average earnings surprise of +48.6%. Despite these positive indicators, which also contribute to a top-tier 'A' VGM score, the stock holds a neutral Zacks Rank of #3 (Hold), suggesting that while its momentum and fundamental characteristics are compelling, the overall quantitative picture does not yet meet the criteria for a 'Buy' rating.

Key Decisions for Investors

• Investors with a momentum-focused strategy should consider the confluence of strong price performance, an 'A' Momentum Score, and a wave of positive upward earnings revisions for fiscal 2025 as a bullish signal.
• It is prudent to weigh the strong momentum and positive analyst sentiment against the neutral Zacks #3 (Hold) rank, which may indicate that certain risk factors or a lack of near-term catalysts are tempering the overall outlook.
• Given the substantial +48.6% average earnings surprise, investors should closely monitor upcoming financial results to validate whether the company can continue to outperform the newly elevated consensus earnings estimates.